Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Lab-on-a-Chip European Congress

Paul Li's Biography



Paul Li, Professor, Simon Fraser University

Dr. Paul Li obtained his Ph.D in analytical chemistry at the University of Toronto in 1995. Then he developed the microfluidic lab-on-a-chip at the University of Alberta during his postdoctoral work. Dr. Li joined Simon Fraser University in 1999, and he was promoted to full professor in 2010. Dr. Li is interested in integrating microfluidics for single-cell analysis in order to study the transport kinetics of chemical compounds (from herbs) on cancer single-cells. This study is particularly useful for characterizing multidrug resistant (MDR) cancer cells, leading to potential improvement in cancer medicine. He is also interested to combine microfluidics with the nucleic acid bioarray for detection of low volumes and low concentrations of fungal pathogenic DNA, KRAS cancer gene DNA, and influenza viral RNA. Dr. Li has published several books, namely“Fundamentals of lab on a chip for biological analysis and discovery” in 2010, and “Microarray Technology: Methods and Applications” in 2016. He is associate editor of Canadian Journal of Pure and Applied Sciences, and sits on the editorial boards of Journal of Proteomics and Genomics and Hong Kong Pharmaceutical Journal. Dr. Li is keynote speaker of several major international conferences. He is inventor of 4 granted patents and 5 pending patents, and founder of ZellChip Technologies Inc. specializing in microfluidic-based instruments for life science applications.

Paul Li Image

Single Cell Analysis on Acute Myleloid Leukemia Patient Cell Samples: Microfluidic Data Collection and Clinical Implications

Monday, 10 March 2014 at 10:45

Add to Calendar ▼2014-03-10 10:45:002014-03-10 11:45:00Europe/LondonSingle Cell Analysis on Acute Myleloid Leukemia Patient Cell Samples: Microfluidic Data Collection and Clinical ImplicationsLab-on-a-Chip European Congress in Berlin, Germany Berlin, Germany SELECTBIOenquiries@selectbiosciences.com

Multidrug resistance (MDR) is the major cause of failure in chemotherapy of acute myeloid leukemia (AML). The reversal effects of MDR inhibitors are investigated to improve chemotherapy sensitivity using a microfluidic method for single-cell measurements.


Add to Calendar ▼2014-03-10 00:00:002014-03-11 00:00:00Europe/LondonLab-on-a-Chip European CongressLab-on-a-Chip European Congress in Berlin, Germany Berlin, Germany SELECTBIOenquiries@selectbiosciences.com